Here's My Prediction For Who Could Acquire Ascendis Pharma

2025-12-15 03:18:34 ET

Thesis

Ascendis Pharma ( ASND ) has stirred up quite the talk with news appearing that the company may be acquired in the near term. They had pretty strong 3Q25 earnings back in November, which saw quite a bit of positive movement for the stock. Their two major treatment lines, Yorvipath and Skytrofa, have just brought in €143.1 and €50.7 million, respectively, and are showing signs of more commercial uptake. The company also has a promising treatment for achondroplasia in the works, with TransCon CNP approaching its PDUFA deadline of February 28th next year. With so much going on, it's no surprise the company has been tipped to get acquired. I see a couple candidates to host a potential acquisition of Ascendis. However, investors should keep in mind that any potential takeover may be dependent on regulatory approval of TransCon CNP, which adds a little bit of risk to buying in next week. Currently, the stock is trading in the $220 range and has been on an upward trend. Year to date, the stock is up about 60%. I'm initiating with a cautious buy rating....

Read the full article on Seeking Alpha

For further details see: